欧州連合 -
オランダ語 -
EMA (European Medicines Agency)
artesunate amivas
amivas ireland ltd - artesunate - malaria - antiprotozoaire - artesunate amivas is indicated for the initial treatment of severe malaria in adults and children. aandacht moet worden gegeven aan de officiële richtlijnen betreffende het juiste gebruik van antimalaria agenten.
欧州連合 -
オランダ語 -
EMA (European Medicines Agency)
skytrofa (previously lonapegsomatropin ascendis pharma)
ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hypofyse en hypothalamische hormonen en analogen - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.
欧州連合 -
オランダ語 -
EMA (European Medicines Agency)
zenalpha
vetcare oy - medetomidine hydrochloride, vatinoxan hydrochloride - psycholeptica, hypnotica en kalmerende middelen - honden - to provide restraint, sedation and analgesia during conduct of non-invasive, non-painful or mildly painful procedures and examinations intended to last no more than 30 minutes.
欧州連合 -
オランダ語 -
EMA (European Medicines Agency)
lutetium (177lu) chloride billev (previously illuzyce)
billev pharma aps - lutetium (177lu) chloride - radionuclide-beeldvorming - therapeutische radiofarmaca - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.
ベルギー -
オランダ語 -
AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)
produodopa 240 mg/ml - 12 mg/ml inf. opl. s.c. flac.
abbvie sa-nv - foslevodopa 240 mg - eq. levodopa 170 mg; foscarbidopa 12 mg - eq. carbidopa 9 mg - oplossing voor infusie - foslevodopa and decarboxylase inhibitor
欧州連合 -
オランダ語 -
EMA (European Medicines Agency)
livtencity
takeda pharmaceuticals international ag ireland branch - maribavir - cytomegalovirus-infecties - antivirale middelen voor systemisch gebruik - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). aandacht moet worden gegeven aan de officiële richtlijnen betreffende het juiste gebruik van antivirale middelen.